CGRP has become an important area of research in migraine treatment, leading to medicines designed to interfere with this pathway. Zavzpret is a CGRP receptor antagonist used for acute migraine treatment in adults. Understanding this medicine also requires understanding the basic role of CGRP in migraine biology.
CGRP stands for calcitonin gene related peptide. Research has established that CGRP plays an important role in migraine mechanisms. Treatments that interfere with CGRP signaling have therefore become an important part of contemporary migraine therapy.
Zavzpret works by blocking CGRP receptors, helping interrupt signaling associated with migraine.
Key characteristics include:
The development of CGRP targeted medicines has expanded the range of options available for people with migraine. Treatment decisions, however, should take into account the individual nature of migraine.
A healthcare professional may evaluate:
The nasal route can also be relevant for individuals who find oral medication difficult to take during migraine attacks. However, suitability should always be determined according to professional medical advice and prescribing information.
Zavzpret demonstrates the growing role of CGRP targeted therapies in acute migraine management. Learning how CGRP receptor antagonism works can provide useful context for understanding newer migraine treatment options. Individual treatment decisions should always involve an appropriate healthcare professional.